Novel acyl sulfonamide LY573636-sodium: Effect on hematopoietic malignant cells

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1237-1242

  Haritunians, Talin ^a   Gueller, Saskia ^a   O'Kelly, Jems ^a   Ilaria Jr , Robert ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Acyl sulfonamides; Hematopoietic malignancies; LY573636; Small molecule drugs

Indexed keywords

LY 573636; N [(5 BROMO 2 THIENYL)SULFONYL] 2,4 DICHLORO SODIUM; REACTIVE OXYGEN METABOLITE; SULFONAMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; N ((5 BROMO 2 THIENYL)SULFONYL) 2,4 DICHLOROBENZAMIDE; N-((5-BROMO-2-THIENYL)SULFONYL)-2,4-DICHLOROBENZAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; GRANULOCYTE; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; PRIORITY JOURNAL; BLOOD DISEASE; DRUG EFFECT; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 58149350373     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000135     Document Type: Article

References (9)

1. Mader MM: Novel antiproliferative antitumor agents. Curr Opin Drug Discov Devel 8: 613-618, 2005.
2. Corbett TH, White K, Polin L, Kushner J, Paluch J, Shih C and Grossman CS: Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs 21: 33-45, 2003.
3. Lobb KL, Hipskind PA, Aikins JA, et al: Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem 47: 5367-5380, 2004.
4. Ilaria RL Jr, Simon GR, Sovak M, et al: Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25: 2515, 2007.
5. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ and Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21: 333-339, 2007.
6. Kumagai T, O'Kelly J, Said JW and Koeffler HP: Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 95: 896-905, 2003.
7. Hisatake J, O'Kelly J, Uskokovic MR, Tomoyasu S and Koeffler HP: Novel vitamin D(3) analog, 21-(3-methyl-3- hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97: 2427-2433, 2001.
8. Green DR and Reed JC: Mitochondria and apoptosis: Science 281: 1309-1312, 1998.
9. Breitman TR, Selonick SE and Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936-2940, 1980.